A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.
Clinical trial NCT00915083 · COMPLETED
Trial details
- NCT number
- NCT00915083
- Sponsor
- Celgene
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2009-06-01
- Primary completion
- 2011-05-01
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.